Efficacy and safety of roflumilast cream for chronic plaque psoriasis with facial/neck and intertriginous area involvement: a post hoc analysis from a randomized controlled trial.

In this post-hoc analysis, IGA clear or almost clear at week 6 was metby more patients treated with roflumilast than patients treated with vehicle (roflumilast 0.3%, 27.2%; roflumilast 0.15%, 22.3%; vehicle, 6.3%; nominal I P i <= 0.026). Https://doi.org/10.1093/bjd/ljad060 DearEditor, Psoriatic lesions can occur on difficult-to-treat areas such as the face or intertriginous regions.[1] While topical corticosteroids may be effective for treating psoriasis, risk of local skin, ocular and systemic side-effects require cautious use, especially in these locations.[2],[3] Topical vitamin D analogues are less effective than corticosteroids and may be associated with local side-effects and should not be applied to facial skin.[[2], [4]] Thus, patients with psoriasis need a topical treatment that is effective and can be used safely on a wide range of anatomical areas without restrictions on treatment duration or site of application. [Extracted from the article]